Ken Palmer Email and Phone Number

*Sold next-generation sequencing libraries to pharmaceuticals, biotech, CRO, and CDMO industries within the Northeast market.*NGS libraries applications: Oncology, WGS, WES sequencing, and gene expression analytics and workflow.

*Spearheaded commercialization efforts for an early-stage company, driving sales of capital equipment specializing in synthetic DNA applications for Antibody discovery, protein engineering, and biologics drugs.*Championed an automated system capable of handling plasmids, DNA libraries, and mRNA, alongside Sanger sequenced verified DNA services.*Built relationships with vital stakeholders within the Biopharma, biotech, research academics, and CRO market segments. Managed complex… Show more *Spearheaded commercialization efforts for an early-stage company, driving sales of capital equipment specializing in synthetic DNA applications for Antibody discovery, protein engineering, and biologics drugs.*Championed an automated system capable of handling plasmids, DNA libraries, and mRNA, alongside Sanger sequenced verified DNA services.*Built relationships with vital stakeholders within the Biopharma, biotech, research academics, and CRO market segments. Managed complex technical sales projects within a team network of customers, research scientists, product management, and field application specialist resulting instrument sales of $518K*Played a key role in product development obtaining KOL biopharmaceutical leveraged automated synthetic biology solutions to reduce critical lead synthesis bottlenecks by 66% and to accelerate antibody discovery timelines to only 6 weeks Show less

*SaaS Medical software analytics start -up *Responsible for business development of Luminare's patented SEPSIS screening software solution. Sagitta, Luminare's early Sepsis detection solution marries EMR data and nursing observation to bring accurate early identification of Sepsis infection. Leveraged 3 hospital relationships for product discussions within 3 months *Developed funnel of $120K software

*Drove the growth of an expansion territory focused on academic teaching hospitals and oncology cancer centers, specializing in the sales of gel and capillary electrophoresis equipment and reagents. Serum protein electrophoresis screening serum and urine samples for protein abnormalities and capillary immunotyping of serum monoclonal proteins. Territory included some of the Americas Best oncology healthcare facilities. *Self- generated, negotiated and closed large IDN Philadelphia Pa… Show more *Drove the growth of an expansion territory focused on academic teaching hospitals and oncology cancer centers, specializing in the sales of gel and capillary electrophoresis equipment and reagents. Serum protein electrophoresis screening serum and urine samples for protein abnormalities and capillary immunotyping of serum monoclonal proteins. Territory included some of the Americas Best oncology healthcare facilities. *Self- generated, negotiated and closed large IDN Philadelphia Pa teaching hospital system resulting in competitive equipment and reagent agreement.Standardized hospital for future capital equipment for 9 hospitals. Developed new business of capital sales and reagents worth $78K in equipment and $34K reagents. Q1-2021 Closed new capital equipment of $82K with additional $32K in reagents *Territory covering Pennsylvania Upstate New York New Jersey. Territory included some of the Americas Best oncology healthcare facilities. Primary market oncology (Multiple Myeloma blood cancer),metabolic disorders such as Diabetes and also Hemoglobinopathy and rare pathologies. Notable Achievements*Achieved exceptional results by surpassing key performance indicators, notably closing influential Integrated Delivery Network (IDN) contracts, surpassing targets by 105% in Q1-2021.*2020 increased funnel of $174K of capital equipment Show less

*Manage and drive IVD capital equipment and reagent sales within the infectious disease market. Capital equipment: RNA nucleic acid extractor NUCLISENS easyMAG, MALDI-TOF (Mass Spectrometer). ID - AST Pathogen, Automated blood culture. Equipment sales ranging $54K- $385K .*Call points: Large academic health systems /IDN and teaching hospitals. Public health in PA/OH/WV. Key stakeholders include: Administration pharmacy, molecular, microbiology lab, IT analytics from various disease test… Show more *Manage and drive IVD capital equipment and reagent sales within the infectious disease market. Capital equipment: RNA nucleic acid extractor NUCLISENS easyMAG, MALDI-TOF (Mass Spectrometer). ID - AST Pathogen, Automated blood culture. Equipment sales ranging $54K- $385K .*Call points: Large academic health systems /IDN and teaching hospitals. Public health in PA/OH/WV. Key stakeholders include: Administration pharmacy, molecular, microbiology lab, IT analytics from various disease test resultsNotable Achievements*Instrumental in growing revenue from $3M to $5M within the infectious disease market, demonstrating strategic prowess and market understanding in driving IVD equipment sales.*Successfully drove innovative technology equipment sales, securing large reagent deals totaling $500-$750K.*Achieved competitive conversions resulting in $571K of new equipment and reagent business in 2018.*Demonstrated exceptional customer retention skills by generating $264K in new equipment sales from existing clients in 2017.*Spearheaded disruptive replacement technology equipment sales amounting to $600K in 2017, showcasing adaptability and product knowledge. Show less

*Implemented strategic initiatives to penetrate and expand market share within university health systems and IDN clinical teaching hospitals. *Fostered collaborative relationships with key stakeholders, including hospital administration,Anatomical Pathologists, laboratory directors, and purchasing managers,GPO within an $3.8M territory.*Proactively identified and capitalized on capital equipment from TMO and key suppliers. including Promega,Luminex Prima, BD ProbeTec, Affirm and BD Max,… Show more *Implemented strategic initiatives to penetrate and expand market share within university health systems and IDN clinical teaching hospitals. *Fostered collaborative relationships with key stakeholders, including hospital administration,Anatomical Pathologists, laboratory directors, and purchasing managers,GPO within an $3.8M territory.*Proactively identified and capitalized on capital equipment from TMO and key suppliers. including Promega,Luminex Prima, BD ProbeTec, Affirm and BD Max, Quidel AmpliVue SeraCare, and Zeptometrix. illumigene Molecular System.*Anatomical Pathology workflow :Capital equipment IHC stainers biopsy processing reagents and cassettes.*Point-Of-Care: Chemistry,Coagulation, Drug of abuse,GI, respiratory disease testing.*Molecular diagnostics: Sample acquisition, extraction and isolation,amplification, detection, data analysis. RT-PCR reagents and probes. RT-qPCR probe based detection kits. RNA purification kits.Accomplishments2014-2015 Increased equipment and reagent by $1M despite consolidation of market. Show less

*Sold variety of analytical instrumentation across diverse markets, including Biotech, Life Science, academic, and research sectors, driving revenue growth and market expansion.Notable Achievements**Received RSD Merit order award in 2010*Awarded growth winner in 2007 and 2009